Table 3 Clinical adverse experience summary
From: Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis
| Â | Sitagliptin 100 mg n (%) (N = 3415) | Non-Exposed n (%) (N = 2724) | Difference in Sitagliptin and Non-Exposed % (95% CI)* |
|---|---|---|---|
With one or more adverse experiences | 2150 (63.0) | 1711 (62.8) | 0.1 (-2.3, 2.6) |
With drug-related adverse experiences†| 440 (12.9) | 483 (17.7) | -4.8 (-6.7, -3.0) |
With serious adverse experiences | 230 (6.7) | 184 (6.8) | -0.0 (-1.3, 1.2) |
With serious drug-related adverse experiences†| 8 (0.2) | 8 (0.3) | -0.1 (-0.4, 0.2) |
Who died | 11 (0.3) | 16 (0.6) | -0.3 (-0.7, 0.1) |
Discontinued due to adverse experiences | 106 (3.1) | 101 (3.7) | -0.6 (-1.5, 0.3) |
Discontinued due to drug-related adverse experiences | 30 (0.9) | 40 (1.5) | -0.6 (-1.2, -0.1) |
Discontinued due to serious adverse experiences | 51 (1.5) | 47 (1.7) | -0.2 (-0.9, 0.4) |
Discontinued due to serious drug-related adverse experiences | 4 (0.1) | 4 (0.1) | -0.0 (-0.3, 0.2) |